G. Berdy

发表

Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease.

B. Reis, D. Tang-Liu, R. Foerster, 2002, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects.

M. Abelson, G. Berdy, M. George, 1992, Archives of ophthalmology.

A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.

D. Spangler, G. Bensch, G. Berdy, 2000, Clinical therapeutics.

Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.

D. Spangler, G. Bensch, G. Berdy, 2001, Clinical therapeutics.

Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis

H. S. Oliff, G. Berdy, 2010 .

Ocular allergic disorders: Disease entities and differential diagnoses

G. Berdy, S. S. Berdy, Susan S. Berdy, 2009, Current allergy and asthma reports.

Angle closure glaucoma precipitated by aerosolized atropine.

L. Hirst, G. Berdy, S. S. Berdy, 1991, Archives of internal medicine.

Lirentelimab for Severe and Chronic Forms of Allergic Conjunctivitis.

P. Asbell, Q. Nguyen, V. Jhanji, 2022, The Journal of allergy and clinical immunology.

D451 CLINICAL ACTIVITY OF AK002, AN ANTI-SIGLEC-8 ANTIBODY, IN SEVERE ALLERGIC CONJUNCTIVITIS AND COMORBID ATOPIC DISEASES

Chen-Yong Lin, V. Jhanji, D. Chu, 2019, Annals of Allergy, Asthma & Immunology.

An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial.

L. Downie, Haixia Liu, P. Simmons, 2019, The ocular surface.

Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.

David T. Douglass, Sameena Haque, P. Simmons, 2019, Contact lens & anterior eye : the journal of the British Contact Lens Association.

Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.

A. Epstein, J. Stoppel, G. Berdy, 2002, Clinical therapeutics.

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study

J. Gira, R. Malhotra, G. Berdy, 2012, Clinical ophthalmology.

Determinants of Outcomes of Adenoviral Keratoconjunctivitis.

Aaron Y. Lee, Cecilia S Lee, Cecilia S. Lee, 2018, Ophthalmology.

The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye

J. Hovanesian, A. Keyser, G. Berdy, 2022, Clinical Ophthalmology (Auckland, N.Z.).

OPTH_A_387111 3841..3849

J. Hovanesian, A. Keyser, G. Berdy, 2022 .

Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitis

R. D. Gross, S. J. Lichtenstein, S. Robertson, 2007, Advances in therapy.

Correction of large amblyopiogenic refractive errors in children using the excimer laser.

L. Tychsen, E. Packwood, G. Berdy, 2005, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

Antihistamines and Mast Cell Stabilizers in Allergic Ocular Disease

M. Abelson, A. Leonardi, G. Berdy, 2008 .

Effect of tear osmolarity on repeatability of keratometry for cataract surgery planning

R. Potvin, Alice T. Epitropoulos, R. Malhotra, 2015, Journal of cataract and refractive surgery.

Ocular allergic disease in the senior patient: diagnosis and management.

G. Berdy, 2000, Allergy and asthma proceedings.

Allergic Conjunctivitis : New Strategies for Treatment Clinicians can better manage allergic conjunctivitis by improving their understanding of their patients ’ mindset and circumstances as well as their ocular health

G. Berdy, 2022 .

Allergic conjunctivitis: a survey of new antihistamines.

M. Abelson, G. Berdy, M. George, 1991, Journal of ocular pharmacology.

The effects of systemic medication on ocular allergic disease.

G. Berdy, 2000, Acta ophthalmologica Scandinavica. Supplement.

Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.

M. Abelson, T. Mundorf, G. Berdy, 2002, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Ocular allergic disorders and dry eye disease: associations, diagnostic dilemmas, and management.

B. Hedqvist, G. Berdy, 2000, Acta ophthalmologica Scandinavica. Supplement.

Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).

J. Ciolino, E. Donnenfeld, P. Karpecki, 2023, Ophthalmology.

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

J. Hovanesian, J. Holladay, G. Berdy, 2021, Clinical ophthalmology.

NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.

S. Krösser, J. Tauber, D. Wirta, 2022, Ophthalmology.